title: Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies.
abstract: Although the benefits of clozapine have been well demonstrated in resistant schizophrenia, the frequency of adverse events is of particular concern: up to 76% of patients to whom clozapine was prescribed experienced an adverse event, with a discontinuation rate of 17%. In addition to its major clinical side effect, agranulocytosis, clozapine is reported to induce inflammatory syndromes with polyserositis. Apart from sparse case reports, no study has yet addressed this particularly interesting issue. With the aim of improving the outcome of clozapine-treated patients, we undertook a review of the literature to characterize the clinical features of clozapine-induced serositis, its pathophysiology, and to propose strategies of clinical management.
authors.affiliation: Center of Psychiatry and Neurosciences, INSERM U894. mouaffakf@yahoo.fr
authors.forename: Fayçal
authors.initials: F
authors.lastname: Mouaffak
authors.forename: Raphael
authors.initials: R
authors.lastname: Gaillard
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Burgess
authors.forename: Hanane
authors.initials: H
authors.lastname: Zaki
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Olié
authors.forename: Marie-Odile
authors.initials: MO
authors.lastname: Krebs
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012700:Serositis / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D028761:Withholding Treatment
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine